Neurostimulation is also utilized extensively in the field of urology and pelvic health, primarily through Sacral Nerve Stimulation (SNS) and Posterior Tibial Nerve Stimulation (PTNS). SNS involves implanting a lead near the sacral nerves, which control the bladder, bowel, and pelvic floor muscles. By modulating the electrical activity of these nerves, SNS is highly effective in treating overactive bladder, urinary and fecal incontinence, and non-obstructive urinary retention in patients who have not responded to conservative treatments.
PTNS offers a less invasive approach for similar conditions: a thin needle electrode is inserted near the posterior tibial nerve in the ankle, and a low-voltage electrical current is delivered, which travels up the nerve pathway to the sacral nerves. While PTNS typically requires regular, in-office treatment sessions, it is often utilized as a low-risk, first-line option before considering permanent implantation with SNS. Both therapies offer a reliable alternative to long-term medication use for challenging pelvic floor disorders.
The proven efficacy of these targeted therapies in restoring crucial bodily functions solidifies the importance of the sacral and tibial nerve stimulation segment. This specialized application addresses a significant area of unmet need and is a consistent contributor to the overall therapeutic equipment profile of the Neuromodulation Devices Market sector.
FAQ 1: How does Sacral Nerve Stimulation (SNS) help with incontinence? SNS implants a lead near the sacral nerves, which control the bladder and bowel, sending electrical impulses to normalize the communication between these organs and the brain, reducing urgency and incontinence.
FAQ 2: What is the main difference between SNS and Posterior Tibial Nerve Stimulation (PTNS)? SNS involves a surgically implanted device for continuous stimulation, while PTNS is a less invasive therapy that typically requires regular, temporary treatments via an electrode placed near the ankle.
Explore more MRFR reports: